Key Points
- Insider Esther Rajavelu sold 40,851 Spero Therapeutics shares for about $42,485, reducing her holdings by 4.14% to 946,000 shares. The sale covered tax withholding obligations tied to vested equity awards.
- Spero shares were reported down 5.6%; the stock opened at $1.01, near its 52-week low of $0.96, and has a market capitalization of about $58.8 million.
- Analysts’ consensus rating is Hold, with an average price target of $6.00. The latest reported quarterly loss of $0.16 per share was slightly better than the $0.17 loss analysts expected.
Spero Therapeutics, Inc. (NASDAQ:SPRO - Get Free Report) insider Esther Rajavelu sold 40,851 shares of the stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $1.04, for a total value of $42,485.04. Following the transaction, the insider owned 946,000 shares in the company, valued at $983,840. This trade represents a 4.14% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Spero Therapeutics Stock Down 5.6%
Spero Therapeutics stock opened at $1.01 on Wednesday. The company has a fifty day simple moving average of $1.15 and a 200-day simple moving average of $1.93. The firm has a market capitalization of $58.82 million, a price-to-earnings ratio of 9.18 and a beta of 1.59. Spero Therapeutics, Inc. has a 52-week low of $0.96 and a 52-week high of $3.08.
Spero Therapeutics (NASDAQ:SPRO - Get Free Report) last announced its quarterly earnings results on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. Spero Therapeutics had a net margin of 24.90% and a return on equity of 16.17%. On average, research analysts anticipate that Spero Therapeutics, Inc. will post -0.97 EPS for the current fiscal year.
Wall Street Analyst Weigh In
A number of brokerages have weighed in on SPRO. Cantor Fitzgerald began coverage on shares of Spero Therapeutics in a research report on Wednesday, October 28th. They set an "overweight" rating and a $6.00 price target for the company. Weiss Ratings raised Spero Therapeutics from a "sell (d+)" rating to a "hold (c-)" rating in a research note on Tuesday. HC Wainwright boosted their price objective on Spero Therapeutics from $5.00 to $6.00 and gave the company a "buy" rating in a report on Monday, September 14th. Compass Point raised Spero Therapeutics to a "neutral" rating in a research note on Monday, September 14th. Finally, Wall Street Zen downgraded Spero Therapeutics from a "hold" rating to a "sell" rating in a research report on Saturday, October 31st. Two research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company's stock. According to data from MarketBeat, the company currently has a consensus rating of "Hold" and an average target price of $6.00.
Check Out Our Latest Research Report on SPRO
Hedge Funds Weigh In On Spero Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in SPRO. Alphabet Inc. purchased a new position in Spero Therapeutics in the second quarter worth approximately $1,967,000. BlackRock Inc. purchased a new stake in shares of Spero Therapeutics in the 2nd quarter valued at approximately $1,314,000. GSA Capital Partners LLP acquired a new stake in shares of Spero Therapeutics in the 2nd quarter valued at $632,000. Global Retirement Partners LLC purchased a new stake in shares of Spero Therapeutics during the 2nd quarter worth $55,000. Finally, Susquehanna Fundamental Investments LLC acquired a new position in shares of Spero Therapeutics during the second quarter worth $36,000. Hedge funds and other institutional investors own 25.60% of the company's stock.
About Spero Therapeutics
(
Get Free Report)
Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company's research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero's lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
